Clinical Edge Journal Scan

Key clinical point: A high proportion of patients with episodic migraine (EM) who achieved an initial response to atogepant showed a sustained response with continued treatment.

Major finding: In the ADVANCE trial, over 70% of participants who achieved an initial ≥50% response with atogepant during the first month sustained their response over 12 weeks. Similarly, in the long-term safety (LTS) trial, 84.7% of those who achieved an initial ≥50% response with atogepant during the first 12 weeks sustained their response through weeks 24-48.

Study details: Findings are from a post hoc analysis of the ADVANCE trial (n = 659) and open-label LTS trial (n = 521) that included patients with EM who were randomly assigned to receive atogepant or placebo once daily for 12 weeks and atogepant or standard care once daily for 52 weeks, respectively.

Disclosures: The study was funded by AbbVie. Some authors declared being full-time employees of or holding stocks in AbbVie or having other ties with various sources.

Source: Lipton RB, Nahas SJ, Pozo-Rosich P, et al. Sustained response to atogepant in episodic migraine: Post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024;25:83 (May 21). doi: 10.1186/s10194-024-01783-6 Source

Key clinical point: A high proportion of patients with episodic migraine (EM) who achieved an initial response to atogepant showed a sustained response with continued treatment.

Major finding: In the ADVANCE trial, over 70% of participants who achieved an initial ≥50% response with atogepant during the first month sustained their response over 12 weeks. Similarly, in the long-term safety (LTS) trial, 84.7% of those who achieved an initial ≥50% response with atogepant during the first 12 weeks sustained their response through weeks 24-48.

Study details: Findings are from a post hoc analysis of the ADVANCE trial (n = 659) and open-label LTS trial (n = 521) that included patients with EM who were randomly assigned to receive atogepant or placebo once daily for 12 weeks and atogepant or standard care once daily for 52 weeks, respectively.

Disclosures: The study was funded by AbbVie. Some authors declared being full-time employees of or holding stocks in AbbVie or having other ties with various sources.

Source: Lipton RB, Nahas SJ, Pozo-Rosich P, et al. Sustained response to atogepant in episodic migraine: Post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024;25:83 (May 21). doi: 10.1186/s10194-024-01783-6 Source

Key clinical point: A high proportion of patients with episodic migraine (EM) who achieved an initial response to atogepant showed a sustained response with continued treatment.

Major finding: In the ADVANCE trial, over 70% of participants who achieved an initial ≥50% response with atogepant during the first month sustained their response over 12 weeks. Similarly, in the long-term safety (LTS) trial, 84.7% of those who achieved an initial ≥50% response with atogepant during the first 12 weeks sustained their response through weeks 24-48.

Study details: Findings are from a post hoc analysis of the ADVANCE trial (n = 659) and open-label LTS trial (n = 521) that included patients with EM who were randomly assigned to receive atogepant or placebo once daily for 12 weeks and atogepant or standard care once daily for 52 weeks, respectively.

Disclosures: The study was funded by AbbVie. Some authors declared being full-time employees of or holding stocks in AbbVie or having other ties with various sources.

Source: Lipton RB, Nahas SJ, Pozo-Rosich P, et al. Sustained response to atogepant in episodic migraine: Post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024;25:83 (May 21). doi: 10.1186/s10194-024-01783-6 Source

Key clinical point: Long-term treatment with oral rimegepant, taken as needed (PRN) or every other day (EOD) plus PRN on nonscheduled days, reduced the need for analgesics or antiemetics in adults with migraine.

Major finding: The proportion of participants who stopped using analgesics or antiemetics after the pre-treatment observation period increased during weeks 1-4 (36.9%), 5-8 (52.6%), and 9-12 (56.5%) following rimegepant treatment in both PRN and PRN plus EOD cohorts.

Study details: This post hoc analysis of an open-label study included 1800 adults with migraine who received rimegepant PRN (n = 1514) or EOD plus PRN (n = 286) for 3 months according to the frequency of attacks, and of whom 80.1% used analgesics or antiemetics during the 30-day pre-treatment observation period.

Disclosures: This study was funded by Biohaven (acquired by Pfizer in October 2022). Terence Fullerton and Glenn Pixton declared being full-time employees of and holding stocks or options in Pfizer, and Glenn Pixton also declared holding stocks in Abbvie.

Source: Fullerton T, Pixton G. Long-term use of rimegepant 75 mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res. 2024;17:1751-1760 (May 2). doi: 10.2147/JPR.S456006 Source

Key clinical point: Long-term treatment with oral rimegepant, taken as needed (PRN) or every other day (EOD) plus PRN on nonscheduled days, reduced the need for analgesics or antiemetics in adults with migraine.

Major finding: The proportion of participants who stopped using analgesics or antiemetics after the pre-treatment observation period increased during weeks 1-4 (36.9%), 5-8 (52.6%), and 9-12 (56.5%) following rimegepant treatment in both PRN and PRN plus EOD cohorts.

Study details: This post hoc analysis of an open-label study included 1800 adults with migraine who received rimegepant PRN (n = 1514) or EOD plus PRN (n = 286) for 3 months according to the frequency of attacks, and of whom 80.1% used analgesics or antiemetics during the 30-day pre-treatment observation period.

Disclosures: This study was funded by Biohaven (acquired by Pfizer in October 2022). Terence Fullerton and Glenn Pixton declared being full-time employees of and holding stocks or options in Pfizer, and Glenn Pixton also declared holding stocks in Abbvie.

Source: Fullerton T, Pixton G. Long-term use of rimegepant 75 mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res. 2024;17:1751-1760 (May 2). doi: 10.2147/JPR.S456006 Source

Key clinical point: Long-term treatment with oral rimegepant, taken as needed (PRN) or every other day (EOD) plus PRN on nonscheduled days, reduced the need for analgesics or antiemetics in adults with migraine.

Major finding: The proportion of participants who stopped using analgesics or antiemetics after the pre-treatment observation period increased during weeks 1-4 (36.9%), 5-8 (52.6%), and 9-12 (56.5%) following rimegepant treatment in both PRN and PRN plus EOD cohorts.

Study details: This post hoc analysis of an open-label study included 1800 adults with migraine who received rimegepant PRN (n = 1514) or EOD plus PRN (n = 286) for 3 months according to the frequency of attacks, and of whom 80.1% used analgesics or antiemetics during the 30-day pre-treatment observation period.

Disclosures: This study was funded by Biohaven (acquired by Pfizer in October 2022). Terence Fullerton and Glenn Pixton declared being full-time employees of and holding stocks or options in Pfizer, and Glenn Pixton also declared holding stocks in Abbvie.

Source: Fullerton T, Pixton G. Long-term use of rimegepant 75 mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res. 2024;17:1751-1760 (May 2). doi: 10.2147/JPR.S456006 Source

Key clinical point: Adherence to an ideal healthy lifestyle and improvement in cardiovascular health (CVH) scores were associated with a significantly lower risk for new-onset migraine.

Major finding: Compared with participants in the poor category of healthy lifestyle index, those in the ideal (adjusted hazard ratio [aHR] 0.81; P < .001) or intermediate (aHR 0.91; P = .035) category had a significantly reduced risk for new-onset migraine. Similarly, participants with high CVH scores had a significantly lower risk for new-onset migraine than those with low CVH scores (aHR 0.73; P = .011).

Study details: This study evaluated the association between healthy lifestyle scores, CVH scores, and migraine in 332,895 participants without migraine (age 37-73 years) from the UK Biobank.

Disclosures: This study was funded by the Interdisciplinary Innovative Talents Foundation of Renmin Hospital at Wuhan University, China, Research on Degree and Graduate Education Teaching Reform at Wuhan University, and others. The authors declared no conflicts of interest.

Source: Lei Y, Zhang L, Shan Z, et al. Poor healthy lifestyle and life's essential 8 are associated with higher risk of new-onset migraine: A prospective cohort study. J Headache Pain. 2024;25:82 (May 17). doi: s10194-024-01785-4 Source

Key clinical point: Adherence to an ideal healthy lifestyle and improvement in cardiovascular health (CVH) scores were associated with a significantly lower risk for new-onset migraine.

Major finding: Compared with participants in the poor category of healthy lifestyle index, those in the ideal (adjusted hazard ratio [aHR] 0.81; P < .001) or intermediate (aHR 0.91; P = .035) category had a significantly reduced risk for new-onset migraine. Similarly, participants with high CVH scores had a significantly lower risk for new-onset migraine than those with low CVH scores (aHR 0.73; P = .011).

Study details: This study evaluated the association between healthy lifestyle scores, CVH scores, and migraine in 332,895 participants without migraine (age 37-73 years) from the UK Biobank.

Disclosures: This study was funded by the Interdisciplinary Innovative Talents Foundation of Renmin Hospital at Wuhan University, China, Research on Degree and Graduate Education Teaching Reform at Wuhan University, and others. The authors declared no conflicts of interest.

Source: Lei Y, Zhang L, Shan Z, et al. Poor healthy lifestyle and life's essential 8 are associated with higher risk of new-onset migraine: A prospective cohort study. J Headache Pain. 2024;25:82 (May 17). doi: s10194-024-01785-4 Source

Key clinical point: Adherence to an ideal healthy lifestyle and improvement in cardiovascular health (CVH) scores were associated with a significantly lower risk for new-onset migraine.

Major finding: Compared with participants in the poor category of healthy lifestyle index, those in the ideal (adjusted hazard ratio [aHR] 0.81; P < .001) or intermediate (aHR 0.91; P = .035) category had a significantly reduced risk for new-onset migraine. Similarly, participants with high CVH scores had a significantly lower risk for new-onset migraine than those with low CVH scores (aHR 0.73; P = .011).

Study details: This study evaluated the association between healthy lifestyle scores, CVH scores, and migraine in 332,895 participants without migraine (age 37-73 years) from the UK Biobank.

Disclosures: This study was funded by the Interdisciplinary Innovative Talents Foundation of Renmin Hospital at Wuhan University, China, Research on Degree and Graduate Education Teaching Reform at Wuhan University, and others. The authors declared no conflicts of interest.

Source: Lei Y, Zhang L, Shan Z, et al. Poor healthy lifestyle and life's essential 8 are associated with higher risk of new-onset migraine: A prospective cohort study. J Headache Pain. 2024;25:82 (May 17). doi: s10194-024-01785-4 Source

Key clinical point: Eptinezumab demonstrated favorable efficacy and tolerability in patients with episodic or chronic migraine resistant to conventional preventive treatments, but its efficacy was compromised in those resistant to calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb).

Major finding: After 3 months of eptinezumab treatment, patients with migraine experienced a reduction in monthly headache days (MHD; −4 days), monthly migraine days (−3 days), and acute medication days (−2 days; P < .001 for all). The 30% responder rates decreased with increase in the number of prior CGRP mAb therapies (none 78.6%; one 45.0%; two 32.1%; three 23.5%; P = .010). Overall, 10.4% of patients reported mild side effects.

Study details: This retrospective real-world analysis included 79 patients with episodic or chronic migraine, of whom 14 had never received anti-CGRP mAb and 65 received anti-CGRP mAb without sufficient effectiveness and with intolerability.

Disclosures: Open access for this study was funded by Projekt DEAL. Some authors declared receiving honoraria, personal fees, travel fees, scientific support, or financial support from or having other ties with various sources.

Source: Scheffler A, Wenzel P, Bendig M, et al. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: A multicentre retrospective real-world analysis from Germany. J Headache Pain. 2024;25:79 (May 16). doi: 10.1186/s10194-024-01788-1 Source

Key clinical point: Eptinezumab demonstrated favorable efficacy and tolerability in patients with episodic or chronic migraine resistant to conventional preventive treatments, but its efficacy was compromised in those resistant to calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb).

Major finding: After 3 months of eptinezumab treatment, patients with migraine experienced a reduction in monthly headache days (MHD; −4 days), monthly migraine days (−3 days), and acute medication days (−2 days; P < .001 for all). The 30% responder rates decreased with increase in the number of prior CGRP mAb therapies (none 78.6%; one 45.0%; two 32.1%; three 23.5%; P = .010). Overall, 10.4% of patients reported mild side effects.

Study details: This retrospective real-world analysis included 79 patients with episodic or chronic migraine, of whom 14 had never received anti-CGRP mAb and 65 received anti-CGRP mAb without sufficient effectiveness and with intolerability.

Disclosures: Open access for this study was funded by Projekt DEAL. Some authors declared receiving honoraria, personal fees, travel fees, scientific support, or financial support from or having other ties with various sources.

Source: Scheffler A, Wenzel P, Bendig M, et al. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: A multicentre retrospective real-world analysis from Germany. J Headache Pain. 2024;25:79 (May 16). doi: 10.1186/s10194-024-01788-1 Source

Key clinical point: Eptinezumab demonstrated favorable efficacy and tolerability in patients with episodic or chronic migraine resistant to conventional preventive treatments, but its efficacy was compromised in those resistant to calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb).

Major finding: After 3 months of eptinezumab treatment, patients with migraine experienced a reduction in monthly headache days (MHD; −4 days), monthly migraine days (−3 days), and acute medication days (−2 days; P < .001 for all). The 30% responder rates decreased with increase in the number of prior CGRP mAb therapies (none 78.6%; one 45.0%; two 32.1%; three 23.5%; P = .010). Overall, 10.4% of patients reported mild side effects.

Study details: This retrospective real-world analysis included 79 patients with episodic or chronic migraine, of whom 14 had never received anti-CGRP mAb and 65 received anti-CGRP mAb without sufficient effectiveness and with intolerability.

Disclosures: Open access for this study was funded by Projekt DEAL. Some authors declared receiving honoraria, personal fees, travel fees, scientific support, or financial support from or having other ties with various sources.

Source: Scheffler A, Wenzel P, Bendig M, et al. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: A multicentre retrospective real-world analysis from Germany. J Headache Pain. 2024;25:79 (May 16). doi: 10.1186/s10194-024-01788-1 Source

Key clinical point: The leptin/body mass index (BMI) ratio was higher in women with psoriatic arthritis (PsA) than in men with the disease and was also associated with pain intensity in women.

Major finding: The leptin/BMI ratio was significantly higher in women than in men (median 0.8 vs 0.2; P < .001). Pain intensity was associated with the leptin/BMI ratio in women (β 0.29; P < .004), while there was no significant association in men (P = .46).

Study details: This observational cross-sectional study included 203 patients with PsA aged 18 years or older, of whom 46.8% were women.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Toledano E, Gómez-Lechón L, Chacón CC, et al. Clinical features and disease activity in psoriatic arthritis: A sex-related perspective on leptin and comorbidity. J Clin Med. 2024;13(10):2959 (May 17). doi: 10.3390/jcm13102959 Source

Key clinical point: The leptin/body mass index (BMI) ratio was higher in women with psoriatic arthritis (PsA) than in men with the disease and was also associated with pain intensity in women.

Major finding: The leptin/BMI ratio was significantly higher in women than in men (median 0.8 vs 0.2; P < .001). Pain intensity was associated with the leptin/BMI ratio in women (β 0.29; P < .004), while there was no significant association in men (P = .46).

Study details: This observational cross-sectional study included 203 patients with PsA aged 18 years or older, of whom 46.8% were women.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Toledano E, Gómez-Lechón L, Chacón CC, et al. Clinical features and disease activity in psoriatic arthritis: A sex-related perspective on leptin and comorbidity. J Clin Med. 2024;13(10):2959 (May 17). doi: 10.3390/jcm13102959 Source

Key clinical point: The leptin/body mass index (BMI) ratio was higher in women with psoriatic arthritis (PsA) than in men with the disease and was also associated with pain intensity in women.

Major finding: The leptin/BMI ratio was significantly higher in women than in men (median 0.8 vs 0.2; P < .001). Pain intensity was associated with the leptin/BMI ratio in women (β 0.29; P < .004), while there was no significant association in men (P = .46).

Study details: This observational cross-sectional study included 203 patients with PsA aged 18 years or older, of whom 46.8% were women.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Toledano E, Gómez-Lechón L, Chacón CC, et al. Clinical features and disease activity in psoriatic arthritis: A sex-related perspective on leptin and comorbidity. J Clin Med. 2024;13(10):2959 (May 17). doi: 10.3390/jcm13102959 Source

Key clinical point: A real-world study showed that old age and initial radiographic damage were potential risk factors, while female sex was a protective factor, for radiographic progression in patients with early psoriatic arthritis (PsA).

Major finding: Female sex (incidence rate ratio [IRR] 0.48; P = .043) was a protective factor, while old age (IRR 1.10; P = .000) and initial radiographic damage (IRR 1.11; P = .000) were risk factors for development of radiographic progression over time. Initial Disease Activity in Psoriatic Arthritis (IRR 1.05; P = .006) and swollen joint count (IRR 1.07; P = .034) could predict radiographic changes in the subgroup of patients with existing progressive damage.

Study details: This study analyzed data from the Dutch South West Psoriatic Arthritis cohort including 476 patients with early PsA of whom 14% demonstrated progressive radiographic damage.

Disclosures: This study was sponsored by an unrestricted grant from Janssen. The authors did not declare any conflicts of interest.

Source: Koc GH, Kok MR, do Rosario Y, et al. Determinants of radiographic progression in early psoriatic arthritis: Insights from a real-world cohort. RMD Open. 2024; 10(2):e004080 (may 24). doi: 10.1136/rmdopen-2024-004080 Source

Key clinical point: A real-world study showed that old age and initial radiographic damage were potential risk factors, while female sex was a protective factor, for radiographic progression in patients with early psoriatic arthritis (PsA).

Major finding: Female sex (incidence rate ratio [IRR] 0.48; P = .043) was a protective factor, while old age (IRR 1.10; P = .000) and initial radiographic damage (IRR 1.11; P = .000) were risk factors for development of radiographic progression over time. Initial Disease Activity in Psoriatic Arthritis (IRR 1.05; P = .006) and swollen joint count (IRR 1.07; P = .034) could predict radiographic changes in the subgroup of patients with existing progressive damage.

Study details: This study analyzed data from the Dutch South West Psoriatic Arthritis cohort including 476 patients with early PsA of whom 14% demonstrated progressive radiographic damage.

Disclosures: This study was sponsored by an unrestricted grant from Janssen. The authors did not declare any conflicts of interest.

Source: Koc GH, Kok MR, do Rosario Y, et al. Determinants of radiographic progression in early psoriatic arthritis: Insights from a real-world cohort. RMD Open. 2024; 10(2):e004080 (may 24). doi: 10.1136/rmdopen-2024-004080 Source

Key clinical point: A real-world study showed that old age and initial radiographic damage were potential risk factors, while female sex was a protective factor, for radiographic progression in patients with early psoriatic arthritis (PsA).

Major finding: Female sex (incidence rate ratio [IRR] 0.48; P = .043) was a protective factor, while old age (IRR 1.10; P = .000) and initial radiographic damage (IRR 1.11; P = .000) were risk factors for development of radiographic progression over time. Initial Disease Activity in Psoriatic Arthritis (IRR 1.05; P = .006) and swollen joint count (IRR 1.07; P = .034) could predict radiographic changes in the subgroup of patients with existing progressive damage.

Study details: This study analyzed data from the Dutch South West Psoriatic Arthritis cohort including 476 patients with early PsA of whom 14% demonstrated progressive radiographic damage.

Disclosures: This study was sponsored by an unrestricted grant from Janssen. The authors did not declare any conflicts of interest.

Source: Koc GH, Kok MR, do Rosario Y, et al. Determinants of radiographic progression in early psoriatic arthritis: Insights from a real-world cohort. RMD Open. 2024; 10(2):e004080 (may 24). doi: 10.1136/rmdopen-2024-004080 Source

Key clinical point: Fibromyalgia and widespread pain were prevalent and associated with elevated disease activity in patients with psoriatic arthritis (PsA).

Major finding: Fibromyalgia and widespread pain were present in 11.1% and 20.6% of patients, respectively. The scores for Clinical Disease Activity in Psoriatic Arthritis were elevated in patients with vs without fibromyalgia (mean difference [Δ] 13.02; 95% CI 10.42-15.63) and in those with vs without widespread pain (Δ 11.94; 95% CI 9.96-13.92). Fibromyalgia was more prevalent in women (P < .001), patients with increased BMI (P = .002), patients diagnosed with spondyloarthritis (P = .005), and patients with a history of cardiovascular diseases (P = .004) and diabetes (P = .007).

Study details: This cross-sectional study included 1823 patients with PsA (age ≥ 18 years) from the CorEvitas US registry.

Disclosures: This study was funded and supported by the Corrona Research Foundation. The data is licensed to the Corrona Research Foundation by CorEvitas, LLC. All authors declared receiving consulting fees or grants from CorEvitas, LLC; Corrona Research Foundation; and other sources.

Source: Mease P, Reed G, Ogdie A, et al. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: Association with disease severity assessment in a large US registry. Arthritis Care Res (Hoboken). 2024 (May 12). doi: 10.1002/acr.25358 Source

Key clinical point: Fibromyalgia and widespread pain were prevalent and associated with elevated disease activity in patients with psoriatic arthritis (PsA).

Major finding: Fibromyalgia and widespread pain were present in 11.1% and 20.6% of patients, respectively. The scores for Clinical Disease Activity in Psoriatic Arthritis were elevated in patients with vs without fibromyalgia (mean difference [Δ] 13.02; 95% CI 10.42-15.63) and in those with vs without widespread pain (Δ 11.94; 95% CI 9.96-13.92). Fibromyalgia was more prevalent in women (P < .001), patients with increased BMI (P = .002), patients diagnosed with spondyloarthritis (P = .005), and patients with a history of cardiovascular diseases (P = .004) and diabetes (P = .007).

Study details: This cross-sectional study included 1823 patients with PsA (age ≥ 18 years) from the CorEvitas US registry.

Disclosures: This study was funded and supported by the Corrona Research Foundation. The data is licensed to the Corrona Research Foundation by CorEvitas, LLC. All authors declared receiving consulting fees or grants from CorEvitas, LLC; Corrona Research Foundation; and other sources.

Source: Mease P, Reed G, Ogdie A, et al. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: Association with disease severity assessment in a large US registry. Arthritis Care Res (Hoboken). 2024 (May 12). doi: 10.1002/acr.25358 Source

Key clinical point: Fibromyalgia and widespread pain were prevalent and associated with elevated disease activity in patients with psoriatic arthritis (PsA).

Major finding: Fibromyalgia and widespread pain were present in 11.1% and 20.6% of patients, respectively. The scores for Clinical Disease Activity in Psoriatic Arthritis were elevated in patients with vs without fibromyalgia (mean difference [Δ] 13.02; 95% CI 10.42-15.63) and in those with vs without widespread pain (Δ 11.94; 95% CI 9.96-13.92). Fibromyalgia was more prevalent in women (P < .001), patients with increased BMI (P = .002), patients diagnosed with spondyloarthritis (P = .005), and patients with a history of cardiovascular diseases (P = .004) and diabetes (P = .007).

Study details: This cross-sectional study included 1823 patients with PsA (age ≥ 18 years) from the CorEvitas US registry.

Disclosures: This study was funded and supported by the Corrona Research Foundation. The data is licensed to the Corrona Research Foundation by CorEvitas, LLC. All authors declared receiving consulting fees or grants from CorEvitas, LLC; Corrona Research Foundation; and other sources.

Source: Mease P, Reed G, Ogdie A, et al. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: Association with disease severity assessment in a large US registry. Arthritis Care Res (Hoboken). 2024 (May 12). doi: 10.1002/acr.25358 Source

Key clinical point: Aortic stiffness was significantly higher in individuals with vs without psoriatic arthritis (PsA), and a longer disease duration was a predictor of increased aortic stiffness in the PsA population.

Major finding: Aortic stiffness, measured by carotid femoral pulse wave velocity, was significantly higher in patients with PsA than in healthy individuals without systemic inflammatory disease (7.80 vs 6.76 m/s; regression coefficient [β] 0.457; P_adj = .034). Aortic stiffness was positively associated with disease duration (β 0.028; P_adj = .020), red cell distribution width (Pearson correlation coefficient 0.190; P = .020), and systolic blood pressure (Spearman correlation coefficient [ρ] 0.351; P < .001), and inversely associated with glomerular filtration rate (ρ −0.264; P = .001).

Study details: This prospective PSOriatic Arthritis CARDiovascular Disease cohort included 150 patients with PsA and 88 healthy individuals without systemic inflammatory disease.

Disclosures: This study did not receive any specific funding. One author declared being an editorial board member of Rheumatology and Therapy. Other authors declared no conflicts of interest.

Source: Triantafyllias K, Liverakos S, Muthuraman M, et al. Cardiovascular risk evaluation in psoriatic arthritis by aortic stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the prospective PSOCARD cohort study. Rheumatol Ther. 2024 (May 31). doi: 10.1007/s40744-024-00676-z Source

Key clinical point: Aortic stiffness was significantly higher in individuals with vs without psoriatic arthritis (PsA), and a longer disease duration was a predictor of increased aortic stiffness in the PsA population.

Major finding: Aortic stiffness, measured by carotid femoral pulse wave velocity, was significantly higher in patients with PsA than in healthy individuals without systemic inflammatory disease (7.80 vs 6.76 m/s; regression coefficient [β] 0.457; P_adj = .034). Aortic stiffness was positively associated with disease duration (β 0.028; P_adj = .020), red cell distribution width (Pearson correlation coefficient 0.190; P = .020), and systolic blood pressure (Spearman correlation coefficient [ρ] 0.351; P < .001), and inversely associated with glomerular filtration rate (ρ −0.264; P = .001).

Study details: This prospective PSOriatic Arthritis CARDiovascular Disease cohort included 150 patients with PsA and 88 healthy individuals without systemic inflammatory disease.

Disclosures: This study did not receive any specific funding. One author declared being an editorial board member of Rheumatology and Therapy. Other authors declared no conflicts of interest.

Source: Triantafyllias K, Liverakos S, Muthuraman M, et al. Cardiovascular risk evaluation in psoriatic arthritis by aortic stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the prospective PSOCARD cohort study. Rheumatol Ther. 2024 (May 31). doi: 10.1007/s40744-024-00676-z Source

Key clinical point: Aortic stiffness was significantly higher in individuals with vs without psoriatic arthritis (PsA), and a longer disease duration was a predictor of increased aortic stiffness in the PsA population.

Major finding: Aortic stiffness, measured by carotid femoral pulse wave velocity, was significantly higher in patients with PsA than in healthy individuals without systemic inflammatory disease (7.80 vs 6.76 m/s; regression coefficient [β] 0.457; P_adj = .034). Aortic stiffness was positively associated with disease duration (β 0.028; P_adj = .020), red cell distribution width (Pearson correlation coefficient 0.190; P = .020), and systolic blood pressure (Spearman correlation coefficient [ρ] 0.351; P < .001), and inversely associated with glomerular filtration rate (ρ −0.264; P = .001).

Study details: This prospective PSOriatic Arthritis CARDiovascular Disease cohort included 150 patients with PsA and 88 healthy individuals without systemic inflammatory disease.

Disclosures: This study did not receive any specific funding. One author declared being an editorial board member of Rheumatology and Therapy. Other authors declared no conflicts of interest.

Source: Triantafyllias K, Liverakos S, Muthuraman M, et al. Cardiovascular risk evaluation in psoriatic arthritis by aortic stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the prospective PSOCARD cohort study. Rheumatol Ther. 2024 (May 31). doi: 10.1007/s40744-024-00676-z Source

Key clinical point: Treatment with biologics significantly reduced the risk for psoriatic arthritis (PsA) development, including peripheral and axial PsA development, in patients with psoriasis.

Major finding: Patients treated at least once vs never treated with biologics had a significantly lower risk for PsA (8.9% vs 26.1%; adjusted odds ratio [aOR] 0.228; P < .001), including for peripheral PsA (aOR 0.182; P < .001) and peripheral PsA with axial involvement (aOR 0.115; P = .039). The protective effect of biologics against PsA persisted irrespective of the class of biologic used.

Study details: Findings are from an analysis of a cohort study that included 1023 patients with psoriasis aged 18 years or older, of whom 29.6% received biologics at least once and 21.0% had PsA.

Disclosures: This study did not receive any specific funding. Four authors declared receiving consulting or speaking fees or having other ties from various sources. Other authors declared no conflicts of interest.

Source: Floris A, Mugheddu C, Sichi L, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024 (May 23). doi: 10.1093/rheumatology/keae257 Source

Key clinical point: Treatment with biologics significantly reduced the risk for psoriatic arthritis (PsA) development, including peripheral and axial PsA development, in patients with psoriasis.

Major finding: Patients treated at least once vs never treated with biologics had a significantly lower risk for PsA (8.9% vs 26.1%; adjusted odds ratio [aOR] 0.228; P < .001), including for peripheral PsA (aOR 0.182; P < .001) and peripheral PsA with axial involvement (aOR 0.115; P = .039). The protective effect of biologics against PsA persisted irrespective of the class of biologic used.

Study details: Findings are from an analysis of a cohort study that included 1023 patients with psoriasis aged 18 years or older, of whom 29.6% received biologics at least once and 21.0% had PsA.

Disclosures: This study did not receive any specific funding. Four authors declared receiving consulting or speaking fees or having other ties from various sources. Other authors declared no conflicts of interest.

Source: Floris A, Mugheddu C, Sichi L, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024 (May 23). doi: 10.1093/rheumatology/keae257 Source

Key clinical point: Treatment with biologics significantly reduced the risk for psoriatic arthritis (PsA) development, including peripheral and axial PsA development, in patients with psoriasis.

Major finding: Patients treated at least once vs never treated with biologics had a significantly lower risk for PsA (8.9% vs 26.1%; adjusted odds ratio [aOR] 0.228; P < .001), including for peripheral PsA (aOR 0.182; P < .001) and peripheral PsA with axial involvement (aOR 0.115; P = .039). The protective effect of biologics against PsA persisted irrespective of the class of biologic used.

Study details: Findings are from an analysis of a cohort study that included 1023 patients with psoriasis aged 18 years or older, of whom 29.6% received biologics at least once and 21.0% had PsA.

Disclosures: This study did not receive any specific funding. Four authors declared receiving consulting or speaking fees or having other ties from various sources. Other authors declared no conflicts of interest.

Source: Floris A, Mugheddu C, Sichi L, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2024 (May 23). doi: 10.1093/rheumatology/keae257 Source

Key clinical point: A dose of 80 mg ixekizumab every 2 (Q2W) or 4 (Q4W) weeks demonstrated rapid and consistent efficacy, regardless of the extent of initial skin involvement in patients with psoriatic arthritis (PsA).

Major finding: In both ixekizumab treatment arms (Q2W and Q4W), over one-third of patients achieved ≥20% improvement in American College of Rheumatology (ACR)20 response as early as week 4, with the number increasing to approximately half at week 24. A similar proportion of patients achieved ACR20/50/70 response at week 24 irrespective of initial psoriasis severity (P > .05).

Study details: This post hoc subgroup analysis of SPIRIT-P1 and SPIRIT-P2 included 655 patients with active PsA and plaque psoriasis who were randomly assigned to receive placebo or 80 mg ixekizumab Q2W or Q4W.

Disclosures: The sponsorship and Rapid Service Fee for this study was funded by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly. Several authors declared receiving grants or honoraria or having other ties with various sources, including Eli Lilly and Company.

Source: Armstrong AW, Jaleel T, Merola JF, et al. Ixekizumab demonstrates rapid and consistent efficacy for patients with psoriatic arthritis, regardless of psoriasis severity. Dermatol Ther (Heidelb). 2024;14:1615-1631 (May 30). Source

Key clinical point: A dose of 80 mg ixekizumab every 2 (Q2W) or 4 (Q4W) weeks demonstrated rapid and consistent efficacy, regardless of the extent of initial skin involvement in patients with psoriatic arthritis (PsA).

Major finding: In both ixekizumab treatment arms (Q2W and Q4W), over one-third of patients achieved ≥20% improvement in American College of Rheumatology (ACR)20 response as early as week 4, with the number increasing to approximately half at week 24. A similar proportion of patients achieved ACR20/50/70 response at week 24 irrespective of initial psoriasis severity (P > .05).

Study details: This post hoc subgroup analysis of SPIRIT-P1 and SPIRIT-P2 included 655 patients with active PsA and plaque psoriasis who were randomly assigned to receive placebo or 80 mg ixekizumab Q2W or Q4W.

Disclosures: The sponsorship and Rapid Service Fee for this study was funded by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly. Several authors declared receiving grants or honoraria or having other ties with various sources, including Eli Lilly and Company.

Source: Armstrong AW, Jaleel T, Merola JF, et al. Ixekizumab demonstrates rapid and consistent efficacy for patients with psoriatic arthritis, regardless of psoriasis severity. Dermatol Ther (Heidelb). 2024;14:1615-1631 (May 30). Source

Key clinical point: A dose of 80 mg ixekizumab every 2 (Q2W) or 4 (Q4W) weeks demonstrated rapid and consistent efficacy, regardless of the extent of initial skin involvement in patients with psoriatic arthritis (PsA).

Major finding: In both ixekizumab treatment arms (Q2W and Q4W), over one-third of patients achieved ≥20% improvement in American College of Rheumatology (ACR)20 response as early as week 4, with the number increasing to approximately half at week 24. A similar proportion of patients achieved ACR20/50/70 response at week 24 irrespective of initial psoriasis severity (P > .05).

Study details: This post hoc subgroup analysis of SPIRIT-P1 and SPIRIT-P2 included 655 patients with active PsA and plaque psoriasis who were randomly assigned to receive placebo or 80 mg ixekizumab Q2W or Q4W.

Disclosures: The sponsorship and Rapid Service Fee for this study was funded by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly. Several authors declared receiving grants or honoraria or having other ties with various sources, including Eli Lilly and Company.

Source: Armstrong AW, Jaleel T, Merola JF, et al. Ixekizumab demonstrates rapid and consistent efficacy for patients with psoriatic arthritis, regardless of psoriasis severity. Dermatol Ther (Heidelb). 2024;14:1615-1631 (May 30). Source